Holen Sie sich die Stockscreener-App
76.20
2.64%
1.8975
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$74.30
Offen:
$74.32
24-Stunden-Volumen:
1.42M
Relative Volume:
0.40
Marktkapitalisierung:
$29.89B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
52.91
EPS:
1.44
Netto-Cashflow:
$570.80M
1W Leistung:
-0.15%
1M Leistung:
-3.80%
6M Leistung:
-11.31%
1J Leistung:
+5.40%
1-Tages-Spanne:
$74.00
$77.24
1-Wochen-Bereich:
$73.47
$77.24
52-Wochen-Spanne:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
76.23 | 29.54B | 4.30B | 571.50M | 570.80M | 1.44 |
|
ABT
Abbott Laboratories
|
130.44 | 230.89B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.93 | 156.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
385.66 | 149.64B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
91.75 | 119.05B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
81.04 | 47.75B | 5.69B | 1.41B | 577.90M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Analyzing DexCom Inc. with risk reward ratio charts2025 Short Interest & High Return Trade Guides - Newser
Will DexCom's (DXCM) Latest Investor Update Hint at a Shifting Innovation Strategy? - simplywall.st
Analyzing drawdowns of DexCom Inc. with statistical toolsTrade Risk Assessment & High Conviction Buy Zone Alerts - Newser
Custom watchlist performance reports with DexCom Inc.July 2025 Market Mood & Scalable Portfolio Growth Ideas - Newser
Market reaction to DexCom Inc.’s recent newsJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - Newser
Understanding DexCom Inc.’s price movementJuly 2025 Breakouts & Expert-Curated Trade Recommendations - Newser
What candlestick patterns are forming on DexCom Inc.2025 Institutional Moves & Weekly Breakout Watchlists - Newser
Exit strategy if you’re trapped in DexCom Inc.July 2025 Analyst Calls & Daily Stock Trend Watchlist - Newser
Using data filters to optimize entry into DexCom Inc.Swing Trade & Safe Investment Capital Preservation Plans - Newser
Ranking DexCom Inc. among high performing stocks via toolsRisk Management & Consistent Profit Alerts - Newser
Custom watchlist performance reports with DexCom IncMarket Performance Report & Fast Moving Stock Watchlists - Newser
DexCom Faces Evaluation Adjustment Amid Strong Financial Performance and Quality Concerns - Markets Mojo
Stock Analysis | Dexcom OutlookWeak Technicals and Mixed Analyst Sentiment - AInvest
Should you hold or exit DexCom Inc. nowTrade Analysis Summary & Free Fast Gain Swing Trade Alerts - Newser
Dexcom Trails Medtronic in Diabetes Tech Race as $330M Volume Marks 343rd Market Rank - AInvest
What to do if you’re stuck in DexCom Inc.Trade Risk Summary & Free High Return Stock Watch Alerts - Newser
DexCom Loses EU Patent For Glucose Sensor Design - Law360
Tools to assess DexCom Inc.’s risk profileQuarterly Risk Review & Low Drawdown Trading Strategies - Newser
Applying Wyckoff theory to DexCom Inc. stockJuly 2025 Pullbacks & Weekly Market Pulse Updates - Newser
Using RSI to spot recovery in DexCom Inc.Index Update & Proven Capital Preservation Methods - Newser
Is DexCom Inc. trending in predictive chart modelsJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Will DexCom Inc. benefit from government policy2025 Market Overview & Community Trade Idea Sharing - khodrobank.com
How to recover losses in DexCom Inc. stockJuly 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - Newser
What data driven models say about DexCom Inc.’s futureJuly 2025 Earnings & Fast Entry and Exit Trade Plans - Newser
How to use a screener to detect DexCom Inc. breakoutsJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - Newser
What is DexCom Inc.’s TAM (Total Addressable Market)Dollar Strength & High Accuracy Trade Alerts - khodrobank.com
Can DexCom Inc. benefit from deglobalization2025 Stock Rankings & Fast Entry High Yield Stock Tips - khodrobank.com
Using R and stats models for DexCom Inc. forecastingWeekly Earnings Recap & Proven Capital Preservation Tips - Newser
Can DexCom Inc. Bounce Back From Weekly Low getLinesFromResByArray error: size == 0 - thegnnews.com
Can trapped investors hope for a rebound in DexCom Inc.Weekly Risk Report & AI Powered Market Entry Strategies - Newser
Will DexCom Inc. continue its uptrendJuly 2025 Macro Moves & High Return Trade Opportunity Guides - Newser
What momentum shifts mean for DexCom Inc.Weekly Market Outlook & Low Volatility Stock Recommendations - Newser
Short interest data insights for DexCom Inc.July 2025 PreEarnings & Verified Swing Trading Watchlists - Newser
Marvell Technology, eBay, And DexCom Are Among Top 10 Large Cap Losers Last Week (August 25-August 29): Are The Others In Your Portfolio? - Benzinga
DexCom P/E Ratio Analysis: Undervalued or Overvalued? - AInvest
Risk adjusted return profile for DexCom Inc. analyzed2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating - Yahoo Finance
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):